Bepotastine Besilate
These highlights do not include all the information needed to use Bepotastine Besilate Ophthalmic Solution safely and effectively. See full prescribing information for Bepotastine Besilate Ophthalmic Solution. Bepotastine Besilate Ophthalmic Solution, for topical ophthalmic useInitial U.S. Approval: 2009
Approved
Approval ID
70430ab5-cd0a-451e-acab-347a2f981898
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Aug 31, 2022
Manufacturers
FDA
Bausch & Lomb Americas Inc.
DUNS: 118287629
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
bepotastine besilate
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
NDC Product Code82260-630
Application NumberNDA022288
Product Classification
M
Marketing Category
C73605
G
Generic Name
bepotastine besilate
Product Specifications
Route of AdministrationOPHTHALMIC
Effective DateAugust 31, 2022
FDA Product Classification
INGREDIENTS (6)
BENZALKONIUM CHLORIDEInactive
Quantity: 0.05 mg in 1 mL
Code: F5UM2KM3W7
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
SODIUM PHOSPHATE, MONOBASIC, DIHYDRATEInactive
Code: 5QWK665956
Classification: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
BEPOTASTINE BESYLATEActive
Quantity: 15 mg in 1 mL
Code: 6W18MO1QR3
Classification: ACTIB